[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587151":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":24,"locations":30,"responsibleParty":53,"collaborators":24,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":24,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":24,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":24,"overallStatus":33,"whyStopped":24,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","this group will receive placebo in addition to the traditional lines of treatment of gout.",[13],"Other: placebo",{"label":15,"type":10,"description":16,"interventionNames":17},"Metformin group","This group will receive metformin (1000mg\u002Fday) in addition to the traditional lines of treatment of gout.",[18],"Drug: Metformin",[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"placebo","Placebo will have the same look of metformin",[9],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"DRUG","Metformin","Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients",[15],[31],{"facility":32,"status":33,"city":34,"state":24,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tanta Unuversity","RECRUITING","Tanta","31527","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.00192,30.78847,{"lat":42,"lon":41},[45,50],{"name":46,"role":47,"phone":48,"phoneExt":24,"email":49},"Mostafa M I Bahaa, PhD","CONTACT","0201025538337","mbahaa@horus.edu.eg",{"name":51,"role":52,"phone":24,"phoneExt":24,"email":24},"Mostafa M Bahaa, PhD","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Mostafa Bahaa","Lecturer","100587151","phase-2-metformin-in-safety-and-efficacy-in-gouty-patients-100587151",false,"NCT06924658","Metformin in Safety and Efficacy in Gouty Patients","the Impact of Metformin Use on Clinical Outcomes in Gouty Patients","Inclusion Criteria:\n\n* Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology\u002FEuropean League Against Rheumatism criteria of gout.\n\nExclusion Criteria:\n\n* Systemic disorders such as cardiovascular, neurological, coronary artery disease.\n* Hypertension, hyperlipidemia, diabetes mellitus, active infections.\n* Other inflammatory or autoimmune diseases.\n* Patients on biologics,\n* Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.","ALL","18 Years","60 Years",{"count":68,"type":69},70,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients",[75],"Gout","2025-06-25",{"date":78,"type":79},"2025-06-27","ACTUAL",{"date":81,"type":79},"2025-04-20",{"date":83,"type":69},"2026-11-20",{"name":55,"class":6},1]